Study: Erbitux prolongs survival of colon cancer patients

11/14/2007 | Forbes · Bloomberg

A Phase III clinical trial of Erbitux found that, when used alone, the drug extended the lives of patients with metastatic colon cancer who have stopped responding to conventional chemotherapy. "These data demonstrate that Erbitux may provide certain colorectal cancer patients with additional time even when other available treatment options have failed," one oncologist said.

View Full Article in:

Forbes · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC